Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cancer specialist Tessera Diagnostics raises $3 million:

This article was originally published in Clinica

Executive Summary

Tessera Diagnostics, a Seattle, Washington-based start-up focusing on cancer, has raised $3.2m in a series A financing round, exceeding its target of $1.75m. Following the initial closing of the round last April, the company started a funded research programme at the University of Pittsburgh. Originally it had access to prostate specific cancer markers; it has now gained an option on colon cancer markers from the university. Tessera is developing highly specific early-stage cancer diagnostics, and is seeking partners for other applications of its markers in imaging, therapeutics and drug discovery. It was founded by president and CEO Robert Masterson and chairman Raymond Cairncross.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT060775

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel